A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1291 participants.

Also called NCT05352815

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,291 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05352815
  • EudraCT 2020-005281-34
Other papers using this trial's data
  • Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial The lancet. Diabetes & endocrinology, 2025-07 DOI, PubMed 40482671

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Bulgaria, China, Croatia, Finland, India, Italy, Japan, Mexico, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, South Africa, South Korea, Taiwan, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05352815. Randomized; no masking; primary purpose treatment. Start 2022-06-01 (actual); primary completion 2024-03-19 (actual). Results posted on 2025-04-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
Acronym
COMBINE 1
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
IcoSema
Intervention (Drug)
Insulin icodec
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05352815
Content hash
aadefcdc26b5e98c87c892b05aa0b6f0dd1bf72ce776b7ee495f1a0024630794